Inhibition of Histone Deacetylase 6 Ameliorates Podocyte Injury in Diabetic Kidney Disease in Mice

HOU Qing, KAN Shuyan, ZHANG Mingchao, XU Feng, LIU Zhihong, JIANG Song

Abstract

To investigate the role of histone deacetylase 6 (HDAC6) in podocyte injury in diabetic kidney disease (DKD) in mice.   Methods  1) The 8-week-old male CD-1 mice were selected to construct the model of DKD with streptozocin (STZ). After the model was established, the mice were intraperitoneally injected with HDAC6 inhibitor CAY10603 (5mg/kg/daily) or same volume vehicle as control. The mice were divided into four groups, control (CTL)+vehicle (Veh) (n=5), CLT+CAY10603 (n=3), STZ+Veh (n=9), and STZ+CAY10603 (n=7). Mice in STZ+Veh and STZ+CAY10603 groups developed DKD, while mice in the CTL+Veh and CTL+CAY10603 groups were served as normal controls. The therapeutic effect was evaluated through urine albumin-to-creatinine ratio (uACR) and renal pathology after the 2-week treatment with CAY10603. 2) Human podocytes were cultured in vitro and were divided into four groups as follows: CTL, transforming growth factor-β (TGFβ), TGFβ+CAY10603 (250 nmol/L), and TGFβ+CAY10603 (500 nmol/L) groups. The control group did not receive any treatment, the last three groups were given 36-h TGFβ treatment at 5 ng/µL, with or without CAY10603 as indicated for an additional 12 h. Western blot was performed to determine the inhibitory effect of CAY10603 on NLRP3 inflammasome. 3) HDAC6 knockout (KO) mice were generated and used to create STZ-induced model of DKD. The mice were divided into four groups: C57BL/6J wild type (WT) (n=6), HDAC6 KO (n=6), WT+STZ (n=10), and HDAC6 KO+STZ (n=9). Samples were collected 16 weeks after successful modeling and changes in uACR and renal pathology were evaluated accordingly.   Results  After 2 weeks of treatment, mice in the STZ+CAY10603 group exhibited reduction in uACR (P<0.05) and inhibition of glomerular mesangium expansion (P<0.05) compared with those of the mice in the STZ+Veh group. There was no statistically significant difference in the indicators between the CTL+Veh group and the CTL+CAY10603 group. In vitro cultured podocytes, compared with the control group, NLRP3 inflammasome activation was seen in the TGFβ group. CAY10603 treatment significantly inhibited the activation of NLRP3 in the dosage-dependent manner (P<0.05). Compared with those of the WT group, the WT+STZ group showed increased uACR (P<0.05), obvious glomerulosclerosis and loss of podocytes numbers. Compared with those of the WT+STZ group, the HDAC6 KO+STZ group showed effectively reduction of uACR (P<0.05) and improvement in the renal pathological changes in mice. There was no significant difference in these aspects between the WT and HDAC6 KO groups.   Conclusion  Inhibition of HDAC6 alleviates proteinuria and podocyte injury in the mouse model of DKD by suppressing the activation of NLRP3 inflammasome.

 

Keywords: Diabetic kidney disease,  Podocytes,  Histone deacetylase 6,  NLRP3 inflammasome

 

Full Text:

PDF


References


LIU M， QIAO Z， ZHANG Y， et al. Histone deacetylases take center stage on regulation of podocyte function. Kidney Dis (Basel)，2020，6(4): 236–246. doi: 10.1159/000507117.

INOUE K， GAN G， CIARLEGLIO M， et al. Podocyte histone deacetylase activity regulates murine and human glomerular diseases. J Clin Invest，2019，129(3): 1295–1313. doi: 10.1172/JCI124030.

WANG X， LIU J， ZHEN J， et al. Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy. Kidney Int，2014， 86(4): 712–725. doi: 10.1038/ki.2014.111.

LIU F， ZONG M， WEN X， et al. Silencing of histone deacetylase 9 expression in podocytes attenuates kidney injury in diabetic nephropathy. Sci Rep，2016，6: 33676. doi: 10.1038/srep33676.

Van BENEDEN K， GEERS C， PAUWELS M， et al. Valproic acid attenuates proteinuria and kidney injury. J Am Soc Nephrol，2011，22(10): 1863–1875. doi: 10.1681/ASN.2010111196.

HE X， SUN T， ZHANG P， et al. Selective inhibition of histone deacetylase class Ⅱa with MC1568 ameliorates podocyte injury. Front Med (Lausanne)，2022，9: 848938. doi: 10.3389/fmed.2022.848938.

REGNA N L， VIESON M D， LUO X M， et al. Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice. Clin Immunol，2016，162: 58–73. doi: 10.1016/j.clim.2015.11.007.

PULYA S， AMIN S A， ADHIKARI N， et al. HDAC6 as privileged target in drug discovery: a perspective. Pharmacol Res，2021，163: 105274. doi: 10.1016/j.phrs.2020.105274.

HOU Q， KAN S， WANG Z， et al. Inhibition of HDAC6 with CAY10603 ameliorates diabetic kidney disease by suppressing NLRP3 inflammasome. Front Pharmacol，2022，13: 938391. doi: 10.3389/fphar. 2022.938391.

LIU Z. Nephrology in China. Nat Rev Nephrol，2013，9(9): 523–528. doi: 10.1038/nrneph.2013.146.

NAGATA M. Podocyte injury and its consequences. Kidney Int，2016， 89(6): 1221–1230. doi: 10.1016/j.kint.2016.01.012.

SHAHZAD K， FATIMA S， KHAWAJA H， et al. Podocyte-specific NLRP3 inflammasome activation promotes diabetic kidney disease. Kidney Int，2022，102(4): 766–779. doi: 10.1016/j.kint.2022.06.010. DOSHI S M， FRIEDMAN A N. Diagnosis and management of type 2 diabetic kidney disease. Clin J Am Soc Nephrol，2017，12(8): 1366–1373. doi: 10.2215/CJN.11111016.

DEFRONZO R A， REEVES W B， AWAD A S. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol， 2021，17(5): 319–334. doi: 10.1038/s41581-021-00393-8.

BAKRIS G L， AGARWAL R， ANKER S D， et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med，2020， 383(23): 2219–2229. doi: 10.1056/NEJMoa2025845.

LECHNER S， MALGAPO M I P， GRÄTZ C， et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat Chem Biol，2022，18(8): 812–820. doi: 10.1038/s41589-022-01015-5.

ZHAO Y， LIANG T， HOU X， et al. Recent development of novel HDAC6 isoform-selective Inhibitors. Curr Med Chem，2021，28(21): 4133–4151. doi: 10.2174/0929867327666201111142653.

LIU L， ZHOU X， SHETTY S， et al. HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury. Toxicol Appl Pharmacol，2019，370: 178–183. doi: 10.1016/j. taap.2019.03.017.


Refbacks

  • There are currently no refbacks.